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ture and the volume of his professional activity, the effects of the
competition and locals’ standards. RESULTS: The behaviour of
the prescription of the physician depend of his type of conven-
tion with the State. At the average, the physicians, who do not
have the convention, prescribe 41 Euro of drugs per act, the
physicians, who have the price of consultation ﬁxed by the State,
prescribe 36 Euro per act and the physicians, who can ﬁx freely
their price, prescribe 30€ per act. The prescription is a regulator
of the level of activity (-3.65 for the physicians without the con-
vention, 0.02 for the rest). We ﬁnd an effect of complement
between the pharmaceutical prescription and the prescription of
sick leaves’ days. Competition has the inﬂuence upon the level
of the regulation. CONCLUSIONS: The result of this study
makes possible to deﬁne the inciting policies on the pharmaceu-
tical regulation to ensure a greater effectiveness of the regulation
of an ambulatory medicine.
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ON OUTCOMES
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OBJECTIVES: In Australia, a drug is subsidised by the govern-
ment only if the Pharmaceutical Beneﬁts Advisory Committee
(PBAC) evaluation has determined the drug to be cost effective.
The government reviewed the quality of industry pharmacoeco-
nomic analyses included in PBAC submission documents and
reported that signiﬁcant problems existed. It is likely, however,
that the PBAC evaluation process itself could contain errors. We
sought to determine the quality of the PBAC evaluations, their
effect on decision-making and the outcomes of PBAC meetings.
METHODS: A survey was conducted to determine industry
experience regarding PBAC decision-making over a period of six
PBAC meetings. The questionnaire was designed to elicit infor-
mation on good and poor decisions, and information needed to
quantify the issues and their effects on submission outcomes. The
questionnaire was divided into 2 sections, the ﬁrst to elicit infor-
mation on good and poor decisions and the second to quantify
the issues and their effects on submission outcomes. RESULTS:
Of 35 questionnaires sent to pharmaceutical companies in 
Australia, 17 replies were received, a response rate of 48%.
These 17 companies had sales that represented 47% of total
pharmaceutical sales. The survey concluded that on average
good decisions were made by the PBAC for only 56% of all sub-
missions. The quality of the PBAC evaluation was related to the
form of economic argument presented and whether the submis-
sion was a ﬁrst or a subsequent (repeat) submission. If the sub-
mission used a cost-minimisation approach, the likelihood of the
evaluation being good was 69%, compared with 38% for sub-
missions that took a cost-effectiveness approach. The likelihood
of a submission’s success was also related to the form of eco-
nomic analysis used, 92% if cost-minimisation was used versus
63% for a cost-effectiveness approach. CONCLUSIONS: Gov-
ernment subsidy decision-making is of variable quality, which
varies the method of economic argument used and affects the
probability of success for submissions.
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OBJECTIVE: Literature suggests that ‘Academic Detailing’ is a
useful ‘evidence-based’ intervention in promoting rational drug
therapy by encouraging appropriate use of cost-effective generic
pharmaceuticals. This study examines possible impact of acade-
mic detailing on trends in change of proportions of generic drug
prescriptions among ambulatory care physicians serving patients
covered by a state health insurance program. METHODS: The
study was conducted using retrospective data available from the
pharmacy beneﬁt management company serving the insurance
program. The target physician population comprised of two
experimental groups (Charleston, n = 251; Morgantown, n =
214)—the top 30th percentile of all the physicians in the areas
chosen based on prescribing volume and average prescription
cost. University-trained academic detailers visited them once
every month and also provided them with educational materials.
A “comparison” group (n = 359) was chosen similarly but was
not visited by a detailer at any time. Monthly generic prescrib-
ing percent were determined for all three groups for a period of
12 months before the intervention and 6 months after the inter-
vention. Two therapeutic classes with ample generic choices—
antibiotics and anti-hypertensives, were studied. RESULTS: In
case of antibiotic prescriptions, while mean increase in percent
generic prescriptions went up in both the experimental groups
(0.26 to 2.41 in Charleston; -0.18 to 2.35 in Morgantown),
mean change in percentage generic prescriptions reduced further
(-0.6 to -3.36) in the comparison group. Though over a much
shorter intervention period—similar trends were observed with
anti-hypertensive prescriptions. In Charleston, there was a sus-
tained (mean rate of change over intervention period = 1.37)
trend in increase in proportion of generic prescriptions while the
proportion declined in the comparison group (mean rate of
change over intervention period = -0.44). CONCLUSIONS:
Academic detailing appears to be a promising strategy for main-
taining or increasing generic prescribing by physicians in ambu-
latory settings.
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OBJECTIVES: The Guidelines is a guidance document to assist
those doing economic evaluations produce standardized and 
reliable economic information for the users of the information
(e.g. decision-makers in Canada’s publicly-funded health care
system). The main changes in this 3rd edition will be discussed.
METHODS: CCOHTA has revised the 1997 edition of the
Guidelines to ensure it remains current, taking into account of
methodological developments and other signiﬁcant changes since
1997. Each Guideline section provides guidance on preferred
methods and advice in areas of controversy. Key stakeholders,
including jurisdictions, industry and methodological experts,
were consulted. Judgement was needed to strike the proper
balance between theoretically ideal vs pragmatic approaches.
RESULTS: Key changes include emphasis on: 1) using cost-
effectiveness and cost-utility analyses; 2) presenting the payer
perspective; 3) using “usual” and recommended care for the
comparator; 4) appropriate analysis of effectiveness parameters;
4) using probabilistic and Bayesian analyses for analyzing uncer-
tainty; 6) using stratiﬁed analysis; and 7) identifying distribu-
tional effects of the technology. Appendices include: 1) guidance
on evaluating non-drug technologies; 2) changes to the stan-
dardized reporting format; 3) guidance on modelling; 4) guid-
ance on reviewing economic studies; 5) quality assurance tips for
doers; and 6) tips for decision-makers on the use and interpre-
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tation of economic evidence. Presenting methods and results in
a transparent manner is a key principle of the Guidelines. CON-
CLUSIONS: The CCOHTA Guidelines for conducting economic
evaluations has been updated. The extent to which those doing
economic evaluations follow the Guidelines, and the degree to
which decision-makers actually use the resulting economic evi-
dence for decision-making, will reﬂect the value of the new
Guidelines.
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OBJECTIVES: To measure the impact different prescription
market basket deﬁnitions have on coverage and inﬂation.
METHODS: January 2001 through December 2002 claims were
extracted for 15 groups. The number of claims, percentage of
the market basket missing (coverage), and inﬂation (using
Laspeyres) were calculated. Days supply and quantity dispensed
were aggregated into different prescription drug market baskets
using each drug’s full NDC, a unique combination of active
ingredient, strength, form, brand/generic, and multi/single
source, brand name and generic name for different units of time
including: monthly, quarterly, semi-annually, and yearly. Inﬂa-
tion was calculated with and without compounds and copaxone.
RESULTS: The number of claims per group ranged from
263,318 to 17,455,237 (with 6 below, 6 above and 3 between 1
to 2 million). Aggregating by NDCs led to the largest gaps in
market basket coverage with between 13% and 38% of NDCs
without a match in a corresponding time periods. The other
methods had gaps in coverage ranging from about 8% to 32%.
Monthly intervals generally had 2 to 3 times the number of
missing days supply (range: 0.05% to 11.1%) or quantity (range:
0.2% to 4.8%) than other time intervals (day supply range:
0.2% to 5.0%, quantity range: 0.1% to 3.0%). Inﬂation ranged
from 6.5% to 15.5% with generally higher values for the deﬁn-
itions using name. CONCLUSIONS: Careful attention should be
paid to how prescription drug market baskets are deﬁned when
comparing or calculating inﬂation. Deﬁning prescriptions drugs
at the lowest possible level, particularly for small populations,
can create systematic gaps in the market basket. Deﬁning the
market basket too broadly can create price variations. Both may
reﬂect quality change bias as well as substitution biases in the
prescription drug market basket.
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OBJECTIVE: To analyze patient and family satisfaction with the
education provided to them during hospitalization. METHODS:
Six quarters of data for the year 2002–2003 obtained from Press-
Ganey surveys based on a Likert Scale with scores of 1 and 5
representing very poor and very good results respectively are
analyzed. Patient Satisfaction (PS) scores with 1) explanation
during tests and treatment, and 2) informing family regarding
condition and treatment are cross tabulated using SPSS with spe-
cialty area and Diagnostic Related Group (DRG) product line.
RESULTS: For the group of explanation during tests and treat-
ments—very good scores are reported from the specialty of areas
of Neonatology (75%), Intensive Care (69%), Neurology (61%)
and Labor and Delivery (57%) while the specialties of Psychia-
try (25%) and Skilled Nursing (35%) have lower proportion of
these scores. The DRG product lines of cardiac catheterization
(65%), dentistry (71%), Neonatology (68%), open heart surgery
(56%) have very good scores while HIV (0%), Psychiatry and
Drug Abuse (32%), Otolaryngology (35%) and Opthalmology
(36%) have lower proportion of these scores. Explanation
during tests and treatment and informing family regarding con-
dition and treatment are signiﬁcantly correlated (p < .01, r =
.544) and the scores are almost similar for the second group. The
overall combined percentage with scores of 4 and 5 on the survey
is 88 percent. CONCLUSION: More effort should be should be
made to convert the scores of 4’s to 5’s. The satisfaction scores
for the specialties of Psychiatry, Skilled Nursing and the DRG of
HIV are areas of concern. Maybe it is the inherent nature of the
conditions encountered in these areas that prevent patients from
having a good understanding of the explanations. Patient edu-
cation and patient satisfaction are closely interlinked and edu-
cating patients does enhance satisfaction scores.
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CONSUMER SATISFACTION WITH HEALTH PLANS AND
DRUG BENEFIT MANAGEMENT STRATEGIES
Sansgiry SS, Sikri S, Kawatkar A
University of Houston, Houston,TX, USA
OBJECTIVES: Managed care has implemented various drug
beneﬁts management strategies like formularies, that most
patients lack understanding of and may lead to dissatisfaction.
The objective of this study was to evaluate consumer satisfaction
with health plans and understand their attitude towards drug
beneﬁt management strategies, particularly the use of drug for-
mularies. METHODS: A cross-sectional study was conducted by
administering a survey to consumers (N = 714) waiting to pick
a prescription in community pharmacies (N = 72) in the Houston
metropolitan area. A prevalidated questionnaire was used to
measure satisfaction with health plan using an eleven-item, ﬁve-
point scale where 1-very dissatisﬁed -5 = very satisﬁed. A 12
item strongly disagree (1)—strongly agree (5) Likert scale was
used to measure consumer perceptions and knowledge regarding
drug formularies. Data along with demographic information
such as age, gender, marital status, race, education and income
were collected, coded, and analyzed at a set priori signiﬁcance
level of 0.05 to perform descriptive and correlation analyses.
RESULTS: Among the surveyed population, only 25% of
patients owned a copy of the formulary. Majority of the respon-
dents were white (43%), female (52%), married (52 %), and
working fulltime (64 %) with a mean age of 39.58 (SD 13.96)
years. Overall, consumers had negative attitude towards formu-
laries 2.77 (SD 0.66). Respondents indicated neutral rating with
respect to satisfaction with drugs included on their formulary 3.0
(SD 0.9). Consumers were somewhat satisﬁed with their health
plans 3.51 (SD 0.73). There was a signiﬁcant (p < 0.05) positive
correlation between satisfaction with health plans and attitude
towards formularies (r = 0.176) as well as with satisfaction with
drug coverage (r = 0.369). CONCLUSIONS: Consumers had
negative attitude toward formularies, which may be attributed
to their lack of knowledge regarding formularies. Patient educa-
tion efforts by health plan providers may help change consumer
attitudes and improve satisfaction.
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